AMH

TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID

AMH as a free ligand exists in 4 entries. Examples include: 1B2I 6NMB 5V3C

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

NameTRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID
Identifiers4-(aminomethyl)cyclohexane-1-carboxylic acid
FormulaC8 H15 N O2
Molecular Weight157.21
TypeNON-POLYMER
Isomeric SMILESNC[C@H]1CC[C@@H](CC1)C(O)=O
InChIInChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-
InChIKeyGYDJEQRTZSCIOI-LJGSYFOKSA-N

Chemical Details

Formal Charge0
Atom Count26
Chiral Atom Count0
Chiral Atomsn/a
Bond Count26
Aromatic Bond Count0
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00302 Different stereochemistry
NameTranexamic Acid
Groupsapproved
DescriptionAntifibrinolytic hemostatic used in severe hemorrhage. [PubChem]
Synonyms
  • Acide tranexamique
  • Acido tranexamico
  • Acidum tranexamicum
  • Cyklokapron
  • Tranexamsaeure
Brand Names
  • Cyklokapron
  • Cyklokapron 100 mg/ml
  • Cyklokapron 500 mg
  • Erfa-tranexamic
  • Gd-tranexamic Acid
Affected OrganismHumans and other mammals
IndicationFor use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.
PharmacologyTranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).
Mechanism of actionTranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.
Route of administration
  • Intravenous
  • Oral
  • Topical
Categories
  • Acids, Carbocyclic
  • Amino Acids
  • Antifibrinolytic Agents
  • Blood and Blood Forming Organs
  • Carboxylic Acids
ATC-CodeB02AA02
AHFS-Code20:28.16
CAS number1197-18-8

Drug Targets

NameSequence SearchPharmacological ActionActions
PlasminogenMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECA...yesinhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682